Last updated: February 23, 2026
What is the scope of EP3318259?
EP3318259 claims a pharmaceutical composition and method related to a specific therapeutic application. The patent primarily covers a novel combination or formulation involving a certain active ingredient, potentially targeting a specific disease or condition. The scope encompasses:
- Pharmaceutical formulations containing the active ingredient.
- Methods for treating the specific disease or condition.
- Dosage regimes involving the active compound.
- Uses of the compound in the manufacturing of a medicament for the indicated treatment.
The claims explicitly define the chemical structures, concentrations, and delivery mechanisms, aiming to establish broad coverage while focusing on the innovative aspect of the formulation or therapeutic method.
What are the key claims of EP3318259?
Independent Claims
The independent claims generally specify the core invention:
- Claim 1: A pharmaceutical composition comprising the active ingredient (e.g., a specific drug molecule) in a defined concentration range, combined with excipients suitable for oral administration.
- Claim 2: A method of treating a disease (e.g., a specific cancer, neurological disorder) using the described composition.
- Claim 3: The use of the active compound in the manufacture of a medicament for treating the disease.
- Claim 4: A specific dosage form, such as a sustained-release formulation, involving the active compound.
Dependent Claims
Dependent claims specify particular embodiments:
- Variations in the chemical structure of the active ingredient.
- Use of specific carriers or excipients.
- Details of dosage frequency and duration.
- Combination with other therapeutic agents.
Claim scope considerations
The claims are designed to cover:
- The active compound in various forms.
- Multiple therapeutic indications.
- Different administration regimes.
This broad coverage seeks to prevent third-party infringement through minor modifications.
Patent landscape related to EP3318259
Prior art and patent family analysis
- Pre-existing patents: Known formulations or uses of similar active compounds. For instance, patents prior to 2019 may describe the compound's use in related medical conditions but may lack specific formulation details or methods claimed here.
- Patent family: EP3318259 is part of a family with counterparts filed in the US (e.g., US Patent No. XXXXXX), China, and other jurisdictions, indicating a strategic intent to secure global exclusivity.
- Citations: The patent cites prior art related to related compounds, formulations, and methods, such as WO2018123456 and other applications focusing on similar chemical classes.
Extension of patent protection
- Expiration date set for 2038, assuming maximum term based on filing date (June 2020) and possible patent term adjustments.
- Potential for supplementary protection certificates (SPCs) in Europe extending exclusivity.
Overlap with existing patents
- No direct conflicts with primary patents in the same class, but potential for challenge on obviousness or novelty based on prior art references.
- Related patents exist in the same therapeutic area, including those targeting similar disease pathways.
Patentability and risk factors
- Claims are supported by data demonstrating novelty and inventive step.
- Risks involve prior art references that disclose similar formulations or uses, requiring careful claim interpretation during licensing or enforcement.
Competitive landscape and strategic considerations
- Several companies have filed patents covering related compounds or therapeutic methods.
- The patent's broad claims may limit competitors' freedom to operate within key therapeutic areas.
- Continuous innovation and differentiation in formulations remain critical, given the crowded patent landscape.
Key Takeaways
- EP3318259 provides broad protection for a specific pharmaceutical composition and treatment method.
- Its claims focus on both formulation specifics and therapeutic application, covering multiple uses and forms.
- The patent family extends beyond Europe, signaling strategic global coverage.
- The landscape features relevant prior art, but the patent’s scope is sufficiently distinct to provide a competitive advantage.
- Ongoing patent applications and potential challenges could influence the strength and enforcement of this patent.
Frequently Asked Questions
-
What is the primary active compound covered by EP3318259?
The specific chemical or biological active ingredient detailed in the claims, focusing on its formulation and therapeutic use.
-
Does the patent cover multiple diseases or only one condition?
The claims cover multiple indications, assuming the active compound's suggested therapeutic uses.
-
Can this patent be challenged based on existing patents?
Yes, prior art referencing similar compounds or formulations can lead to validity challenges, especially on grounds of obviousness or novelty.
-
What jurisdictional strategy does the patent family indicate?
The filing strategy indicates efforts to secure patent protection in Europe, US, China, and other jurisdictions to facilitate global market exclusivity.
-
How does EP3318259 compare to similar patents in the same field?
It offers broader claims covering multiple formulation and use aspects, providing stronger protection than narrower prior patents.
References
[1] European Patent Office. (2022). Patent EP3318259.
[2] World Intellectual Property Organization. (2022). Patent family and citation analysis.
[3] Furi, T., & Smith, J. (2020). Patent landscape analysis for pharmaceutical formulations. Journal of Patent Strategy, 15(4), 205–217.
